Stomach Cancer Trial, Recruiting (NCT05804331)

Stomach Cancer Trial, Recruiting NCT05804331 Sponsor: Western Sydney Local Health District Condition: Stomach Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05804331 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stomach Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older.
People who have a growth or abnormal tissue in the upper digestive tract (such as the stomach or oesophagus) that is larger than 10mm, and where the growth is located in one of the following layers of the digestive tract wall: the inner lining (mucosa) or just beneath it (submucosa), a deeper muscle layer (muscularis propria), or a combination of these layers — depending on the type of procedure being considered (confirm with trial site).

Who may not be able to join:

People under 18 years of age.
People who are unable to give their own informed consent to participate.
People who are pregnant or currently breastfeeding.
People who have a condition that affects normal blood clotting, or who are taking certain blood-thinning medications (such as clopidogrel, prasugrel, warfarin, or dabigatran) and are unable to safely stop these medications around the time of the procedure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Bourke, WSLHD

Phone: 02 8890 5555

Australian sites

Westmead Hospital, Sydney, New South Wales

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05804331

Sponsor: Western Sydney Local Health District

Phase: Not Applicable

Status: Recruiting

Condition: Stomach Cancer

Trial contact: 02 8890 5555

More information: https://clinicaltrials.gov/study/NCT05804331

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older.
People who have a growth or abnormal tissue in the upper digestive tract (such as the stomach or oesophagus) that is larger than 10mm, and where the growth is located in one of the following layers of the digestive tract wall: the inner lining (mucosa) or just beneath it (submucosa), a deeper muscle layer (muscularis propria), or a combination of these layers — depending on the type of procedure being considered (confirm with trial site).

Who may not be able to join:

People under 18 years of age.
People who are unable to give their own informed consent to participate.
People who are pregnant or currently breastfeeding.
People who have a condition that affects normal blood clotting, or who are taking certain blood-thinning medications (such as clopidogrel, prasugrel, warfarin, or dabigatran) and are unable to safely stop these medications around the time of the procedure.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Western Sydney Local Health District

Registry

ClinicalTrials.gov

Start date

14 March 2023

Est. completion

14 March 2028

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection; Safety: intra and post procedural; bleeding; perforation; anaesthetic; Long term outcomes: recurrent and residual disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov